Cannabis Ruderalis

thcscience_admin
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
4,967,788 edits
Add: pmc, pmid, pages, issue, volume, journal, date, title, authors 1-28. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webform
Graeme Bartlett (talk | contribs)
Administrators
237,096 edits
 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{Short description|Drug for the treatment of hepatitis C}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
{{Infobox drug
| drug_name = Coblopasvir
| drug_name = Coblopasvir
Line 52: Line 54:
| UNII = 67XWL3R65W
| UNII = 67XWL3R65W
| DrugBank = DB15315
| DrugBank = DB15315
| IUPHAR_ligand =
| ChemSpiderID = 75531292
| KEGG = D12247
| ChEBI =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
<!-- Chemical and physical data -->
<!-- Chemical and physical data -->
| IUPAC_name = Methyl ''N''-[(2''S'')-1-[(2''S'')-2-[5-[4-[7-[2-[(2''S'')-1-[(2''S'')-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1''H''-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1''H''-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
| IUPAC_name = Methyl ''N''-[(2''S'')-1-[(2''S'')-2-[5-[4-[7-[2-[(2''S'')-1-[(2''S'')-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1''H''-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1''H''-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
| C = 41 | H = 50 | N = 8 | O = 8
| C = 41 | H = 50 | N = 8 | O = 8
| StdInChI = InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1
| StdInChI_comment =
| StdInChIKey = JBYJTCVXUMWTJJ-YRCZKMHPSA-N
}}
}}


'''Coblopasvir''' is a pharmaceutical drug for the treatment of [[hepatitis C]].<ref>{{cite journal | doi = 10.1111/jvh.13208 | title = Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis | date = 2020 | last1 = Rao | first1 = Huiying | last2 = Song | first2 = Guangjun | last3 = Li | first3 = Guangming | last4 = Yang | first4 = Yongfeng | last5 = Wu | first5 = Xiaofeng | last6 = Guan | first6 = Yujuan | last7 = Mao | first7 = Qing | last8 = Jiang | first8 = Xiangjun | last9 = Wang | first9 = Changyuan | last10 = Zhang | first10 = Ying | last11 = Jia | first11 = Jidong | last12 = Guo | first12 = Xiaolin | last13 = Li | first13 = Chenghao | last14 = Ning | first14 = Jing | last15 = Qin | first15 = Hong | last16 = Pan | first16 = Hai | last17 = Wei | first17 = Lai | journal = Journal of Viral Hepatitis | volume = 27 | issue = 1 | pages = 45–51 | pmid = 31520460 }}</ref>
'''Coblopasvir''' is a pharmaceutical drug for the treatment of [[hepatitis C]].<ref>{{cite journal | vauthors = Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, Mao Q, Jiang X, Wang C, Zhang Y, Jia J, Guo X, Li C, Ning J, Qin H, Pan H, Wei L | title = Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis | journal = Journal of Viral Hepatitis | volume = 27 | issue = 1 | pages = 45–51 | date = January 2020 | pmid = 31520460 | doi = 10.1111/jvh.13208 }}</ref> It is a pan-genotypic inhibitor of HCV [[NS5A|nonstructural protein 5A]].<ref name = "Gao_2020" />


In China, it is approved for use in combination with [[sofosbuvir]] for treating naïve or [[interferon]]‐experienced adults chronically monoinfected patients with [[Hepatitis C virus|HCV]] of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.<ref>{{cite journal | doi = 10.1111/liv.14633 | title = Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial | date = 2020 | last1 = Gao | first1 = Yanhang | last2 = Kong | first2 = Fei | last3 = Li | first3 = Guangming | last4 = Li | first4 = Cheng | last5 = Zheng | first5 = Sujun | last6 = Lin | first6 = Jianmei | last7 = Wen | first7 = Xiaofeng | last8 = Hu | first8 = Jinghua | last9 = Wang | first9 = Xiaozhong | last10 = Wu | first10 = Xiaofeng | last11 = Xing | first11 = Huichun | last12 = Jia | first12 = Jidong | last13 = Jia | first13 = Zhansheng | last14 = Guan | first14 = Yujuan | last15 = Li | first15 = Chenghao | last16 = Wu | first16 = Guicheng | last17 = Gao | first17 = Zhiliang | last18 = Mou | first18 = Zhuangbo | last19 = Ning | first19 = Qin | last20 = Mao | first20 = Qing | last21 = Yang | first21 = Yongfeng | last22 = Ning | first22 = Jing | last23 = Li | first23 = Li | last24 = Pan | first24 = Hai | last25 = Zhou | first25 = Desheng | last26 = Ding | first26 = Yanhua | last27 = Qin | first27 = Hong | last28 = Niu | first28 = Junqi | journal = Liver International | volume = 40 | issue = 11 | pages = 2685–2693 | pmid = 33047868 | pmc = 7702130 }}</ref>
In China, it is approved for use in combination with [[sofosbuvir]] for treating naïve or [[interferon]]‐experienced adults chronically monoinfected patients with [[Hepatitis C virus|HCV]] of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.<ref name = "Gao_2020">{{cite journal | vauthors = Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, Wen X, Hu J, Wang X, Wu X, Xing H, Jia J, Jia Z, Guan Y, Li C, Wu G, Gao Z, Mou Z, Ning Q, Mao Q, Yang Y, Ning J, Li L, Pan H, Zhou D, Ding Y, Qin H, Niu J | title = Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial | journal = Liver International | volume = 40 | issue = 11 | pages = 2685–2693 | date = November 2020 | pmid = 33047868 | pmc = 7702130 | doi = 10.1111/liv.14633 }}</ref>


==References==
== References ==
{{reflist}}
{{reflist}}

{{RNA antivirals}}


[[Category:NS5A inhibitors]]
[[Category:NS5A inhibitors]]
Line 69: Line 83:
[[Category:Methyl esters]]
[[Category:Methyl esters]]
[[Category:Carbamates]]
[[Category:Carbamates]]
[[Category:Isopropyl compounds]]
[[Category:Pyrrolidines]]


{{antiinfective-drug-stub}}
{{antiinfective-drug-stub}}

Latest revision as of 08:10, 11 May 2024

Coblopasvir
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • Methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC41H50N8O8
Molar mass782.899 g·mol−1
  • InChI=InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1
  • Key:JBYJTCVXUMWTJJ-YRCZKMHPSA-N

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.[2]

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.[2]

References[edit]

  1. ^ Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, et al. (January 2020). "Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis". Journal of Viral Hepatitis. 27 (1): 45–51. doi:10.1111/jvh.13208. PMID 31520460.
  2. ^ a b Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, et al. (November 2020). "Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial". Liver International. 40 (11): 2685–2693. doi:10.1111/liv.14633. PMC 7702130. PMID 33047868.
source: https://en.wikipedia.org/w/index.php?title=Coblopasvir&diff=1223312934&oldid=1219884462

Leave a Reply